Back
Bensa_2025_Wiley_ksa.70230
Journal article

Safety profile comparison of intra‐articular corticosteroids, hyaluronic acid, platelet‐rich plasma, and cell‐based injections for knee osteoarthritis : a systematic review and meta‐analysis by the ESSKA Orthobiologics Initiative

  • Bensa, Alessandro ORCID Service of Orthopaedics and Traumatology, Department of Surgery, EOC, Lugano, Switzerland - Faculty of Biomedical Sciences, Università della Svizzera italiana, Switzerland
  • Piano, Andrea Service of Orthopaedics and Traumatology, Department of Surgery, EOC, Lugano, Switzerland
  • Fumagalli, Giacomo Arthur Service of Orthopaedics and Traumatology, Department of Surgery, EOC, Lugano, Switzerland
  • de Girolamo, Laura Orthopaedic Biotechnology Laboratory, IRCCS Ospedale Galeazzi Sant'Ambrogio, Milan, Italy
  • Laver, Lior Department of Orthopaedics, Hillel Yaffe Medical Center (HYMC), Hadera, Israel - Arthrosport Clinic, Tel-Aviv, Israel - Rappaport Faculty of Medicine, Technion University Hospital (Israel Institute of Technology), Haifa, Israel
  • Magalon, Jérémy Cell Therapy Laboratory, Hôpital De La Conception, AP-HM, Marseille, France - INSERM, NRA, C2VN, Aix Marseille Univ, France - Remedex Network, Marseille, France
  • Sánchez, Mikel Arthroscopic Surgery Unit, MiKS Hospital, Vitoria-Gasteiz, Spain - Advanced Biological Therapy Unit, MiKS Hospital, Vitoria-Gasteiz, Spain
  • Tischer, Thomas Department of Orthopaedic Surgery, University of Rostock, Germany - Department of Orthopaedic and Trauma Surgery, Malteser Waldkrankenhaus St. Marien, Erlangen, Germany
  • Filardo, Giuseppe ORCID Service of Orthopaedics and Traumatology, Department of Surgery, EOC, Lugano, Switzerland - Faculty of Biomedical Sciences, Università della Svizzera italiana, Switzerland
Show more…
  • 2025
Published in:
  • Knee Surgery, Sports Traumatology, Arthroscopy. - 2025, p. ksa.70230
Adverse events
Infection
Knee
Osteoarthritis
Safety
English Purpose: The aim was to compare the safety profiles of corticosteroids (CS), hyaluronic acid (HA), blood-derived products based on platelet concentrates (for simplicity indicated as PRP - platelet-rich plasma - being PRP the most common product), and cell-based therapies (namely products exploiting the therapeutic function of mesenchymal stromal cells and other cell populations, either expanded or prepared at the point of care) for knee osteoarthritis (OA) injective treatment. Methods: The literature search was conducted on PubMed, Cochrane, and Web of Science according to PRISMA guidelines on clinical studies reporting adverse events of CS, HA, PRP, or cell-based therapies. Number of patients with adverse events and number and type of adverse events were collected for each treatment. A meta-analysis was conducted for each product on the total, non-severe, severe adverse events, and on the infection rate. Results: Out of 848 included studies, 559 reported data on the adverse events in 76,061 patients and were used for the meta-analysis. These studies included 7121 patients treated with CS, 51,146 patients with HA, 11,941 patients with PRP, and 5853 patients with cell-based therapies. The rates of patients reporting at least one adverse event were 11.0% for CS, 10.5% for HA, 8.7% for PRP, and 14.7% for cell-based therapies. The mean number of total adverse events per treated patient was 0.21 for CS, 0.13 for HA, 0.05 for PRP, and 0.19 for cell-based therapies, with a significant difference in each individual comparison (p < 0.001) except for CS versus cell-based therapies. The same trend was observed for non-severe adverse events. The rates of severe adverse events were 1.1% for CS, 0.7% for HA, 0.3% for PRP, and 0.5% for cell-based therapies, while infection rates were 0.4% for CS, 0.1% for HA, 0.3% for PRP, and 0.4% for cell-based therapies. Conclusion: CS, HA, PRP, and cell-based therapies for knee OA have different safety profiles. PRP presented the lowest total adverse event rate, followed by HA, cell-based therapies, and CS. The same trend was observed for non-severe adverse events. PRP demonstrated the lowest rate of severe adverse events, followed by cell-based therapies, HA, and CS, while HA showed the lowest infection rate followed by PRP, CS, and cell-based therapies. Level of Evidence: Level IV.
Collections
Language
  • English
Classification
Medicine
License
CC BY
Open access status
hybrid
Identifiers
  • ISSN 0942-2056, 1433-7347
  • DOI 10.1002/ksa.70230
  • RICERCO 67679
  • ARK ark:/12658/srd1335504
Persistent URL
https://n2t.net/ark:/12658/srd1335504
Statistics
Document views: 6 File downloads:
  • Bensa_2025_Wiley_ksa.70230: 3